366 related articles for article (PubMed ID: 26691296)
1. The 'Omics' of Amyotrophic Lateral Sclerosis.
Caballero-Hernandez D; Toscano MG; Cejudo-Guillen M; Garcia-Martin ML; Lopez S; Franco JM; Quintana FJ; Roodveldt C; Pozo D
Trends Mol Med; 2016 Jan; 22(1):53-67. PubMed ID: 26691296
[TBL] [Abstract][Full Text] [Related]
2. Amyotrophic lateral sclerosis: the complex path to precision medicine.
Talbot K; Feneberg E; Scaber J; Thompson AG; Turner MR
J Neurol; 2018 Oct; 265(10):2454-2462. PubMed ID: 30054789
[TBL] [Abstract][Full Text] [Related]
3. [Update on fundamental and clinical research in amyotrophic lateral sclerosis].
Pradat PF; Camdessanché JP; Carluer L; Cintas P; Corcia P; Danel-Brunaud V; Echaniz-Laguna A; Gonzalez J; Nicolas G; Vandenberghe N; Verschueren A;
Rev Neurol (Paris); 2009; 165(6-7):532-41. PubMed ID: 19419744
[TBL] [Abstract][Full Text] [Related]
4. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
[TBL] [Abstract][Full Text] [Related]
5. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Weishaupt JH; Hyman T; Dikic I
Trends Mol Med; 2016 Sep; 22(9):769-783. PubMed ID: 27498188
[TBL] [Abstract][Full Text] [Related]
6. Neuropathology and omics in motor neuron diseases.
Tanaka F; Ikenaka K; Yamamoto M; Sobue G
Neuropathology; 2012 Aug; 32(4):458-62. PubMed ID: 22187969
[TBL] [Abstract][Full Text] [Related]
7. Further development of biomarkers in amyotrophic lateral sclerosis.
Blasco H; Vourc'h P; Pradat PF; Gordon PH; Andres CR; Corcia P
Expert Rev Mol Diagn; 2016 Aug; 16(8):853-68. PubMed ID: 27275785
[TBL] [Abstract][Full Text] [Related]
8. Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology.
Vucic S; Kiernan MC
Handb Clin Neurol; 2013; 116():561-75. PubMed ID: 24112924
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders.
Goutman SA
Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1332-1359. PubMed ID: 28968365
[TBL] [Abstract][Full Text] [Related]
10. Management and therapeutic perspectives in amyotrophic lateral sclerosis.
Mathis S; Couratier P; Julian A; Vallat JM; Corcia P; Le Masson G
Expert Rev Neurother; 2017 Mar; 17(3):263-276. PubMed ID: 27644548
[TBL] [Abstract][Full Text] [Related]
11. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic.
Mancuso R; Navarro X
Prog Neurobiol; 2015 Oct; 133():1-26. PubMed ID: 26253783
[TBL] [Abstract][Full Text] [Related]
12. Evolving markers in amyotrophic lateral sclerosis.
Chen X; Zhou L; Cui C; Sun J
Adv Clin Chem; 2023; 114():225-246. PubMed ID: 37268333
[TBL] [Abstract][Full Text] [Related]
13. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients.
Millecamps S; De Septenville A; Teyssou E; Daniau M; Camuzat A; Albert M; LeGuern E; Galimberti D; ; Brice A; Marie Y; Le Ber I
Neurobiol Aging; 2014 Dec; 35(12):2882.e13-2882.e15. PubMed ID: 25158920
[TBL] [Abstract][Full Text] [Related]
15. From use of omics to systems biology: Identifying therapeutic targets for amyotrophic lateral sclerosis.
Castelli L; Vasta R; Allen SP; Waller R; Chiò A; Traynor BJ; Kirby J
Int Rev Neurobiol; 2024; 176():209-268. PubMed ID: 38802176
[TBL] [Abstract][Full Text] [Related]
16. The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis.
Nonneman A; Robberecht W; Van Den Bosch L
Neurodegener Dis Manag; 2014; 4(3):223-39. PubMed ID: 25095817
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis.
Van Damme P; Robberecht W
Curr Opin Neurol; 2013 Oct; 26(5):466-72. PubMed ID: 23945281
[TBL] [Abstract][Full Text] [Related]
18. Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis.
Kjældgaard AL; Pilely K; Olsen KS; Pedersen SW; Lauritsen AØ; Møller K; Garred P
Mol Immunol; 2018 Oct; 102():14-25. PubMed ID: 29933890
[TBL] [Abstract][Full Text] [Related]
19. Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact?
Coatti GC; Beccari MS; Olávio TR; Mitne-Neto M; Okamoto OK; Zatz M
Cytometry A; 2015 Mar; 87(3):197-211. PubMed ID: 25645594
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for amyotrophic lateral sclerosis.
Bowser R; Cudkowicz M; Kaddurah-Daouk R
Expert Rev Mol Diagn; 2006 May; 6(3):387-98. PubMed ID: 16706741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
